Health economics Study Guide

📖 Core Concepts Health Economics – studies efficiency, effectiveness, value, and behavior in producing and consuming health and health‑care. Third‑Party Payer – insurer (or employer) pays for the services the patient receives, often masking the true price and quality. Asymmetric Information – patients know less than providers about the necessity and quality of care. Externalities – health actions affect third parties (e.g., vaccination protects others; opioid misuse harms the community). Health as Capital (Grossman Model) – health is a durable stock that depreciates over time; individuals invest to maintain it. Utility Function – $U(X,H)$ where $X$ = other goods, $H$ = health stock; utility derives from both consumption and health. Market Failures – adverse selection, moral hazard, supplier‑induced demand, monopoly power. Cost‑Utility Analysis – compares incremental cost‑effectiveness ratios (ICER) to QALYs (quality‑adjusted life years). --- 📌 Must Remember Definition – Health economics = study of efficiency, effectiveness, value, behavior in health/health‑care. Arrow (1963) – Laid the modern foundation of health economics. Optimal Investment Condition – Marginal Cost of health capital = Marginal Benefit. Utility – $U(X,H)$; health is a durable good that depreciates. Key Market Failures Adverse Selection: high‑risk individuals self‑select into insurance. Moral Hazard: insured patients use more care because they bear less cost. Supplier‑Induced Demand: providers push services for financial gain. Cost‑Utility – Agencies (e.g., NICE) use ICER = $\frac{\Delta C}{\Delta QALY}$ to decide reimbursement. Monopoly Indicators – Few hospitals, patent‑protected drugs, or private insurers → ↑prices. Regulation Goal – Correct market failures, ensure access, curb excessive profit margins. --- 🔄 Key Processes Grossman Investment Decision Estimate marginal cost of additional health capital (e.g., medical spending). Estimate marginal benefit (extra utility from better health). Invest until MC = MB; adjust for age, wages, education. Cost‑Utility Analysis (CUA) Identify intervention and comparator. Measure costs ($\Delta C$) and health outcomes in QALYs ($\Delta QALY$). Compute ICER = $\Delta C / \Delta QALY$. Compare ICER to willingness‑to‑pay threshold. Health Technology Assessment (HTA) Workflow Clinical effectiveness review. Economic evaluation (CEA/CUA). Budget impact analysis. Policy recommendation & reimbursement decision. --- 🔍 Key Comparisons Adverse Selection vs. Moral Hazard Adverse Selection: risk‑type influences who enrolls. Moral Hazard: insurance coverage influences how much care is used. Cost‑Effectiveness vs. Cost‑Utility vs. Cost‑Benefit CEA: outcomes in natural units (e.g., lives saved). CUA: outcomes in QALYs (quality‑adjusted). CBA: outcomes monetized (dollar value of benefits). Health vs. Health‑Care Services Health: overall well‑being, influenced by genetics, environment, behavior. Health‑Care: medical services that treat or maintain health. --- ⚠️ Common Misunderstandings “Health = Health‑Care” – health is broader; many determinants lie outside the medical system. Price Visibility – insurance hides true price; assuming price reflects quality is false. Depreciation vs. Aging – health stock depreciates due to wear‑and‑tear, not just chronological age. Moral Hazard ≠ Adverse Selection – they operate at different stages (use vs. enrollment). --- 🧠 Mental Models / Intuition Health as a Durable Asset – think of health like a car: you must maintain (service, fuel) to prevent depreciation, but you also derive ongoing utility from driving it. Risk Pooling Analogy – a community pot where everyone contributes a small amount; large individual losses are shared, reducing personal financial risk. Market Failure “Leak” – when information or incentives are imperfect, “leaks” appear as over‑use (moral hazard) or adverse enrollment (adverse selection). --- 🚩 Exceptions & Edge Cases Underinsurance – high‑cost diseases (cancer, pandemics) may be excluded or priced out of private markets. Monopoly Power – physician‑owned hospitals can inflate margins; regulation may be required. Practice Variation – large geographic differences often signal supplier‑induced demand rather than patient need. --- 📍 When to Use Which Choose CUA when outcomes are best expressed in quality‑adjusted life years (e.g., chronic disease interventions). Use CEA for interventions with a clear natural‑unit outcome (e.g., number of surgeries avoided). Apply MC = MB rule for personal health‑investment decisions (exercise, screening). Implement Copayments to curb moral hazard; risk‑adjusted premiums to mitigate adverse selection. --- 👀 Patterns to Recognize Hidden Price/Quality → look for insurance‑driven wording (“covered”, “benefit”) rather than explicit cost. Geographic Treatment Clusters → likely supplier‑induced demand or practice variation. High Copayment + Low Utilization → insurer targeting moral hazard. Externality Mention → indicates potential market failure (e.g., vaccination campaigns). --- 🗂️ Exam Traps Confusing Adverse Selection with Moral Hazard – remember the former is about who joins, the latter about how much they use. Assuming Price Equals Quality – insurance often decouples the two. Treating All Markets as Competitive – health markets frequently exhibit monopoly or oligopoly features. Mixing Up Cost‑Utility with Cost‑Benefit – CUA uses QALYs, CBA converts outcomes to dollar terms. Neglecting Depreciation – health capital declines over time; ignoring this yields overly optimistic investment levels.